The DOI matches its Crossref record; 151 of the 151 references it cites were found in a registry or an index.
PD-1–PD-L1 immune-checkpoint blockade in B-cell lymphomas
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Coiffier, B., Lepage, E., Brière, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011795 · Cited by 5,574
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2006) · Nature · doi:10.1038/nature04444 · Cited by 3,986
Rosenwald, A., Wright, G., Chan, W. C., Connors, J. M., Campo, E., Fisher, R. I., Gascoyne, R. D., Muller-Hermelink, H. K., Smeland, E. B., Giltnane, J. M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012914 · Cited by 3,829
Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Ansell, S. M., Lesokhin, A. M., Borrello, I., Halwani, A., Scott, E. C., Gutierrez, M., Schuster, S. J., Millenson, M. M., Cattry, D., Freeman, G. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411087 · Cited by 3,560
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237
Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192461099 · Cited by 3,203
Molecular mechanisms of T cell co-stimulation and co-inhibition
Chen, L., & Flies, D. B. (2013) · Nature Reviews Immunology · doi:10.1038/nri3405 · Cited by 3,114
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781
Follicular Helper CD4 T Cells (T FH )
Crotty, S. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101400 · Cited by 2,738
PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression
Day, C. L., Kaufmann, D. E., Kiepiela, P., Brown, J. A., Moodley, E. S., Reddy, S., Mackey, E. W., Miller, J. D., Leslie, A. J., DePierres, C., et al. (2006) · Nature · doi:10.1038/nature05115 · Cited by 2,680
Weber, J. S., D'Angelo, S. P., Minor, D., Hodi, F. S., Gutzmer, R., Neyns, B., Hoeller, C., Khushalani, N. I., Miller, W. H., Lao, C. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70076-8 · Cited by 2,676
Shipp, M. A., Ross, K. N., Tamayo, P., Weng, A. P., Kutok, J. L., Aguiar, R. C. T., Gaasenbeek, M., Angelo, M., Reich, M., Pinkus, G. S., et al. (2002) · Nature Medicine · doi:10.1038/nm0102-68 · Cited by 2,428
Appio, L., Landoni, C., La Targia, M., Bertolli, V., Chiarucci, M., Crovetti, G., Vassenna, E., Serio, G., & Bregni, M. (2017) · Chemotherapy · doi:10.1159/000458147 · Cited by 2,327
Taube, J. M., Klein, A., Brahmer, J. R., Xu, H., Pan, X., Kim, J. H., Chen, L., Pardoll, D. M., Topalian, S. L., & Anders, R. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3271 · Cited by 2,324
PD-L1 expression as a predictive biomarker in cancer immunotherapy
Patel, S. P., & Kurzrock, R. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0983 · Cited by 2,291
Self-citationTopalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Brahmer, J. R., Lawrence, D. P., Atkins, M. B., Powderly, J. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.0105 · Cited by 2,222
Atkins, M. B., Lotze, M. T., Dutcher, J. P., Fisher, R. I., Weiss, G., Margolin, K., Abrams, J., Sznol, M., Parkinson, D., Hawkins, M., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.7.2105 · Cited by 2,048
Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001
Morton, L. M., Wang, S. S., Devesa, S. S., Hartge, P., Weisenburger, D. D., & Linet, M. S. (2006) · Blood · doi:10.1182/blood-2005-06-2508 · Cited by 1,683
Gisselbrecht, C., Glass, B., Mounier, N., Singh Gill, D., Linch, D. C., Trneny, M., Bosly, A., Ketterer, N., Shpilberg, O., Hagberg, H., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.1618 · Cited by 1,625
Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction
Trautmann, L., Janbazian, L., Chomont, N., Said, E. A., Gimmig, S., Bessette, B., Boulassel, M.-R., Delwart, E., Sepulveda, H., Balderas, R. S., et al. (2006) · Nature Medicine · doi:10.1038/nm1482 · Cited by 1,565
Younes, A., Gopal, A. K., Smith, S. E., Ansell, S. M., Rosenblatt, J. D., Savage, K. J., Ramchandren, R., Bartlett, N. L., Cheson, B. D., de Vos, S., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.0410 · Cited by 1,529
Dave, S. S., Wright, G., Tan, B., Rosenwald, A., Gascoyne, R. D., Chan, W. C., Fisher, R. I., Braziel, R. M., Rimsza, L. M., Grogan, T. M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041869 · Cited by 1,418
Green, M. R., Monti, S., Rodig, S. J., Juszczynski, P., Currie, T., O'Donnell, E., Chapuy, B., Takeyama, K., Neuberg, D., Golub, T. R., et al. (2010) · Blood · doi:10.1182/blood-2010-05-282780 · Cited by 1,305
Rosenberg, S. A. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03510360033032 · Cited by 1,131
Bcl-2 initiates a new category of oncogenes: regulators of cell death
Korsmeyer, S. (1992) · Blood · doi:10.1182/blood.v80.4.879.879 · Cited by 1,122
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
Lokhorst, H. M., Plesner, T., Laubach, J. P., Nahi, H., Gimsing, P., Hansson, M., Minnema, M. C., Lassen, U., Krejcik, J., Palumbo, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506348 · Cited by 1,117
Salles, G., Seymour, J. F., Offner, F., López-Guillermo, A., Belada, D., Xerri, L., Feugier, P., Bouabdallah, R., Catalano, J. V., Brice, P., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62175-7 · Cited by 1,079
Lesokhin, A. M., Ansell, S. M., Armand, P., Scott, E. C., Halwani, A., Gutierrez, M., Millenson, M. M., Cohen, A. D., Schuster, S. J., Lebovic, D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.9789 · Cited by 1,001
Sehn, L. H., Donaldson, J., Chhanabhai, M., Fitzgerald, C., Gill, K., Klasa, R., MacPherson, N., O'Reilly, S., Spinelli, J. J., Sutherland, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.137 · Cited by 987
Krejcik, J., Casneuf, T., Nijhof, I. S., Verbist, B., Bald, J., Plesner, T., Syed, K., Liu, K., van de Donk, N. W. C. J., Weiss, B. M., et al. (2016) · Blood · doi:10.1182/blood-2015-12-687749 · Cited by 954
Chen, B. J., Chapuy, B., Ouyang, J., Sun, H. H., Roemer, M. G. M., Xu, M. L., Yu, H., Fletcher, C. D. M., Freeman, G. J., Shipp, M. A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0855 · Cited by 843
Dubovsky, J. A., Beckwith, K. A., Natarajan, G., Woyach, J. A., Jaglowski, S., Zhong, Y., Hessler, J. D., Liu, T.-M., Chang, B. Y., Larkin, K. M., et al. (2013) · Blood · doi:10.1182/blood-2013-06-507947 · Cited by 810
Benson, D. M., Bakan, C. E., Mishra, A., Hofmeister, C. C., Efebera, Y., Becknell, B., Baiocchi, R. A., Zhang, J., Yu, J., Smith, M. K., et al. (2010) · Blood · doi:10.1182/blood-2010-02-271874 · Cited by 807
CTLA-4 ligation blocks CD28-dependent T cell activation.
Walunas, T. L., Bakker, C. Y., & Bluestone, J. A. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.6.2541 · Cited by 801
PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome
Roemer, M. G. M., Advani, R. H., Ligon, A. H., Natkunam, Y., Redd, R. A., Homer, H., Connelly, C. F., Sun, H. H., Daadi, S. E., Freeman, G. J., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.4482 · Cited by 791
Marzec, M., Zhang, Q., Goradia, A., Raghunath, P. N., Liu, X., Paessler, M., Wang, H. Y., Wysocka, M., Cheng, M., Ruggeri, B. A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810958105 · Cited by 728
Good-Jacobson, K. L., Szumilas, C. G., Chen, L., Sharpe, A. H., Tomayko, M. M., & Shlomchik, M. J. (2010) · Nature Immunology · doi:10.1038/ni.1877 · Cited by 691
Davis, T. A., Grillo-López, A. J., White, C. A., McLaughlin, P., Czuczman, M. S., Link, B. K., Maloney, D. G., Weaver, R. L., Rosenberg, J., & Levy, R. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.17.3135 · Cited by 687
Green, M. R., Rodig, S., Juszczynski, P., Ouyang, J., Sinha, P., O'Donnell, E., Neuberg, D., & Shipp, M. A. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1942 · Cited by 685
Berger, R., Rotem-Yehudar, R., Slama, G., Landes, S., Kneller, A., Leiba, M., Koren-Michowitz, M., Shimoni, A., & Nagler, A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4079 · Cited by 680
Armand, P., Shipp, M. A., Ribrag, V., Michot, J.-M., Zinzani, P. L., Kuruvilla, J., Snyder, E. S., Ricart, A. D., Balakumaran, A., Rose, S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.3467 · Cited by 670
Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers
Kataoka, K., Shiraishi, Y., Takeda, Y., Sakata, S., Matsumoto, M., Nagano, S., Maeda, T., Nagata, Y., Kitanaka, A., Mizuno, S., et al. (2016) · Nature · doi:10.1038/nature18294 · Cited by 651
Ipilimumab for Patients with Relapse after Allogeneic Transplantation
Davids, M. S., Kim, H. T., Bachireddy, P., Costello, C., Liguori, R., Savell, A., Lukez, A. P., Avigan, D., Chen, Y.-B., McSweeney, P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1601202 · Cited by 593
Targetable genetic features of primary testicular and primary central nervous system lymphomas
Chapuy, B., Roemer, M. G. M., Stewart, C., Tan, Y., Abo, R. P., Zhang, L., Dunford, A. J., Meredith, D. M., Thorner, A. R., Jordanova, E. S., et al. (2016) · Blood · doi:10.1182/blood-2015-10-673236 · Cited by 585
Advances in biology of multiple myeloma: clinical applications
Hideshima, T., Bergsagel, P. L., Kuehl, W. M., & Anderson, K. C. (2004) · Blood · doi:10.1182/blood-2004-01-0037 · Cited by 582
Ziepert, M., Hasenclever, D., Kuhnt, E., Glass, B., Schmitz, N., Pfreundschuh, M., & Loeffler, M. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.2493 · Cited by 581
Liu, J., Hamrouni, A., Wolowiec, D., Coiteux, V., Kuliczkowski, K., Hetuin, D., Saudemont, A., & Quesnel, B. (2007) · Blood · doi:10.1182/blood-2006-10-051482 · Cited by 580
Dose-Adjusted EPOCH-Rituximab Therapy in Primary Mediastinal B-Cell Lymphoma
Dunleavy, K., Pittaluga, S., Maeda, L. S., Advani, R., Chen, C. C., Hessler, J., Steinberg, S. M., Grant, C., Wright, G., Varma, G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214561 · Cited by 569
Thompson, R. H., Dong, H., Lohse, C. M., Leibovich, B. C., Blute, M. L., Cheville, J. C., & Kwon, E. D. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2599 · Cited by 569
Sehn, L. H., & Gascoyne, R. D. (2015) · Blood · doi:10.1182/blood-2014-05-577189 · Cited by 560
Westin, J. R., Chu, F., Zhang, M., Fayad, L. E., Kwak, L. W., Fowler, N., Romaguera, J., Hagemeister, F., Fanale, M., Samaniego, F., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70551-5 · Cited by 529
Atkins, M. B., Kunkel, L., Sznol, M., & Rosenberg, S. A. (2000) · PubMed · Cited by 515
Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma
Marshall, N. A., Christie, L. E., Munro, L. R., Culligan, D. J., Johnston, P. W., Barker, R. N., & Vickers, M. A. (2004) · Blood · doi:10.1182/blood-2003-07-2594 · Cited by 509
Wu, C., Zhu, Y., Jiang, J., Zhao, J., Zhang, X.-G., & Xu, N. (2006) · Acta Histochemica · doi:10.1016/j.acthis.2006.01.003 · Cited by 495
Nakanishi, J., Wada, Y., Matsumoto, K., Azuma, M., Kikuchi, K., & Ueda, S. (2007) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-006-0266-z · Cited by 473
Banga, R., Procopio, F. A., Noto, A., Pollakis, G., Cavassini, M., Ohmiti, K., Corpataux, J.-M., de Leval, L., Pantaleo, G., & Perreau, M. (2016) · Nature Medicine · doi:10.1038/nm.4113 · Cited by 471
Kiyasu, J., Miyoshi, H., Hirata, A., Arakawa, F., Ichikawa, A., Niino, D., Sugita, Y., Yufu, Y., Choi, I., Abe, Y., et al. (2015) · Blood · doi:10.1182/blood-2015-02-629600 · Cited by 464
Sagiv-Barfi, I., Kohrt, H. E. K., Czerwinski, D. K., Ng, P. P., Chang, B. Y., & Levy, R. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1500712112 · Cited by 444
Armand, P., Nagler, A., Weller, E. A., Devine, S. M., Avigan, D. E., Chen, Y.-B., Kaminski, M. S., Holland, H. K., Winter, J. N., Mason, J. R., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.3685 · Cited by 440
Fisher, R. I., Rosenberg, S. A., & Fyfe, G. (2000) · PubMed · Cited by 439
PD-1–PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma
Yamamoto, R., Nishikori, M., Kitawaki, T., Sakai, T., Hishizawa, M., Tashima, M., Kondo, T., Ohmori, K., Kurata, M., Hayashi, T., et al. (2008) · Blood · doi:10.1182/blood-2007-05-085159 · Cited by 401
Chen, R., Gopal, A. K., Smith, S. E., Ansell, S. M., Rosenblatt, J. D., Savage, K. J., Connors, J. M., Engert, A., Larsen, E. K., Huebner, D., et al. (2016) · Blood · doi:10.1182/blood-2016-02-699850 · Cited by 395
Inadequate T follicular cell help impairs B cell immunity during HIV infection
Cubas, R. A., Mudd, J. C., Savoye, A.-L., Perreau, M., van Grevenynghe, J., Metcalf, T., Connick, E., Meditz, A., Freeman, G. J., Abesada-Terk, G., et al. (2013) · Nature Medicine · doi:10.1038/nm.3109 · Cited by 371
Dorfman, D. M., Brown, J. A., Shahsafaei, A., & Freeman, G. J. (2006) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000209855.28282.ce · Cited by 358
Blazar, B. R., Carreno, B. M., Panoskaltsis-Mortari, A., Carter, L., Iwai, Y., Yagita, H., Nishimura, H., & Taylor, P. A. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.3.1272 · Cited by 329
Andorsky, D. J., Yamada, R. E., Said, J., Pinkus, G. S., Betting, D. J., & Timmerman, J. M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2660 · Cited by 328
Rossille, D., Gressier, M., Damotte, D., Maucort-Boulch, D., Pangault, C., Semana, G., Le Gouill, S., Haioun, C., Tarte, K., Lamy, T., et al. (2014) · Leukemia · doi:10.1038/leu.2014.137 · Cited by 322
Twa, D. D. W., Chan, F. C., Ben-Neriah, S., Woolcock, B. W., Mottok, A., Tan, K. L., Slack, G. W., Gunawardana, J., Lim, R. S., McPherson, A. W., et al. (2014) · Blood · doi:10.1182/blood-2013-10-535443 · Cited by 302
Carreras, J., Lopez-Guillermo, A., Roncador, G., Villamor, N., Colomo, L., Martinez, A., Hamoudi, R., Howat, W. J., Montserrat, E., & Campo, E. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0513 · Cited by 296
Shankar, P., Russo, M., Harnisch, B., Patterson, M., Skolnik, P., & Lieberman, J. (2000) · Blood · doi:10.1182/blood.v96.9.3094 · Cited by 285
Kim, J. R., Moon, Y. J., Kwon, K. S., Bae, J. S., Wagle, S., Kim, K. M., Park, H. S., Lee, H., Moon, W. S., Chung, M. J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082870 · Cited by 285
Nicolae, A., Pittaluga, S., Abdullah, S., Steinberg, S. M., Pham, T. A., Davies-Hill, T., Xi, L., Raffeld, M., & Jaffe, E. S. (2015) · Blood · doi:10.1182/blood-2015-02-630632 · Cited by 282
Witzig, T. E., Wiernik, P. H., Moore, T., Reeder, C., Cole, C., Justice, G., Kaplan, H., Voralia, M., Pietronigro, D., Takeshita, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.1169 · Cited by 260
Genetic and Epigenetic Regulation of PD-1 Expression
Bally, A. P. R., Austin, J. W., & Boss, J. M. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1502643 · Cited by 243
Gowrishankar, K., Gunatilake, D., Gallagher, S. J., Tiffen, J., Rizos, H., & Hersey, P. (2015) · PLOS ONE · doi:10.1371/journal.pone.0123410 · Cited by 230
Tamura, H., Ishibashi, M., Yamashita, T., Tanosaki, S., Okuyama, N., Kondo, A., Hyodo, H., Shinya, E., Takahashi, H., Dong, H., et al. (2013) · Leukemia · doi:10.1038/leu.2012.213 · Cited by 225
B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders
Wilcox, R. A., Feldman, A. L., Wada, D. A., Yang, Z.-Z., Comfere, N. I., Dong, H., Kwon, E. D., Novak, A. J., Markovic, S. N., Pittelkow, M. R., et al. (2009) · Blood · doi:10.1182/blood-2009-04-216671 · Cited by 221
Flinn, I. W., Kahl, B. S., Leonard, J. P., Furman, R. R., Brown, J. R., Byrd, J. C., Wagner-Johnston, N. D., Coutre, S. E., Benson, D. M., Peterman, S., et al. (2014) · Blood · doi:10.1182/blood-2013-11-538546 · Cited by 210
The molecular pathogenesis of primary mediastinal large B-cell lymphoma
Steidl, C., & Gascoyne, R. D. (2011) · Blood · doi:10.1182/blood-2011-05-326538 · Cited by 206
The role of B7 family molecules in hematologic malignancy
Greaves, P., & Gribben, J. G. (2013) · Blood · doi:10.1182/blood-2012-10-385591 · Cited by 187
Jungbluth, A. A., Ely, S., DiLiberto, M., Niesvizky, R., Williamson, B., Frosina, D., Chen, Y.-T., Bhardwaj, N., Chen-Kiang, S., Old, L. J., et al. (2005) · Blood · doi:10.1182/blood-2004-12-4931 · Cited by 182
Kozako, T., Yoshimitsu, M., Fujiwara, H., Masamoto, I., Horai, S., White, Y., Akimoto, M., Suzuki, S., Matsushita, K., Uozumi, K., et al. (2009) · Leukemia · doi:10.1038/leu.2008.272 · Cited by 178
Xerri, L., Chetaille, B., Seriari, N., Attias, C., Guillaume, Y., Arnoulet, C., & Olive, D. (2008) · Human Pathology · doi:10.1016/j.humpath.2007.11.012 · Cited by 172
Molecular Pathogenesis of Follicular Lymphoma: A Cross Talk of Genetic and Immunologic Factors
de Jong, D. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.26.856 · Cited by 171
Role of PD-1 co-inhibitory pathway in HIV infection and potential therapeutic options
Velu, V., Shetty, R. D., Larsson, M., & Shankar, E. M. (2015) · Retrovirology · doi:10.1186/s12977-015-0144-x · Cited by 170
Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas
Menter, T., Bodmer-Haecki, A., Dirnhofer, S., & Tzankov, A. (2016) · Human Pathology · doi:10.1016/j.humpath.2016.03.005 · Cited by 165
Shi, M., Roemer, M. G. M., Chapuy, B., Liao, X., Sun, H. H., Pinkus, G. S., Shipp, M. A., Freeman, G. J., & Rodig, S. J. (2014) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000297 · Cited by 164
How I treat HIV-associated lymphoma
Dunleavy, K., & Wilson, W. H. (2012) · Blood · doi:10.1182/blood-2011-08-373738 · Cited by 164
Lenalidomide enhances anti-myeloma cellular immunity
Luptakova, K., Rosenblatt, J., Glotzbecker, B., Mills, H., Stroopinsky, D., Kufe, T., Vasir, B., Arnason, J., Tzachanis, D., Zwicker, J. I., et al. (2013) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-012-1308-3 · Cited by 162
Straub, M., Drecoll, E., Pfarr, N., Weichert, W., Langer, R., Hapfelmeier, A., Götz, C., Wolff, K.-D., Kolk, A., & Specht, K. (2016) · Oncotarget · doi:10.18632/oncotarget.7593 · Cited by 161
Follicular lymphoma: evolving therapeutic strategies
Kahl, B. S., & Yang, D. T. (2016) · Blood · doi:10.1182/blood-2015-11-624288 · Cited by 161
Myklebust, J. H., Irish, J. M., Brody, J., Czerwinski, D. K., Houot, R., Kohrt, H. E., Timmerman, J., Said, J., Green, M. R., Delabie, J., et al. (2013) · Blood · doi:10.1182/blood-2012-04-421826 · Cited by 158
Immunosuppressive Effects of Multiple Myeloma Are Overcome by PD-L1 Blockade
Hallett, W. H. D., Jing, W., Drobyski, W. R., & Johnson, B. D. (2011) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2011.03.011 · Cited by 152
Yamamoto, R., Nishikori, M., Tashima, M., Sakai, T., Ichinohe, T., Takaori‐Kondo, A., Ohmori, K., & Uchiyama, T. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01302.x · Cited by 147
Hao, Y., Chapuy, B., Monti, S., Sun, H. H., Rodig, S. J., & Shipp, M. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3007 · Cited by 141
Barrett, M. T., Anderson, K. S., Lenkiewicz, E., Andreozzi, M., Cunliffe, H. E., Klassen, C. L., Dueck, A. C., McCullough, A. E., Reddy, S., Ramanathan, R. K., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4494 · Cited by 135
Diagnosis and management of lymphomas and other cancers in HIV-infected patients
Carbone, A., Vaccher, E., Gloghini, A., Pantanowitz, L., Abayomi, A., Paoli, P. D., & Franceschi, S. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.31 · Cited by 134
How I treat HIV-associated multicentric Castleman disease
Bower, M. (2010) · Blood · doi:10.1182/blood-2010-07-290213 · Cited by 134
Blazar, B. R., Taylor, P. A., Panoskaltsis‐Mortari, A., Sharpe, A. H., & Vallera, D. A. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.11.6368 · Cited by 131
Ikeda, S., Goodman, A. M., Cohen, P. R., Jensen, T. J., Ellison, C. K., Frampton, G. M., Miller, V. A., Patel, S. P., & Kurzrock, R. (2016) · npj Genomic Medicine · doi:10.1038/npjgenmed.2016.37 · Cited by 130
Self-citationMiyoshi, H., Kiyasu, J., Kato, T., Yoshida, N., Shimono, J., Yokoyama, S., Taniguchi, H., Sasaki, Y., Kurita, D., Kawamoto, K., et al. (2016) · Blood · doi:10.1182/blood-2016-02-698936 · Cited by 127
Dunleavy, K. M., & Wilson, W. H. (2014) · Blood · doi:10.1182/blood-2014-05-575092 · Cited by 124
Review of the cardiac long‐term effects of therapy for Hodgkin lymphoma
Ng, A. K. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08713.x · Cited by 121
Smeltzer, J. P., Jones, J. M., Ziesmer, S. C., Grote, D. M., Xiu, B., Ristow, K. M., Yang, Z. Z., Nowakowski, G. S., Feldman, A. L., Cerhan, J. R., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2367 · Cited by 119
Nanda, R., Chow, L. Q. M., Dees, E. C., Berger, R., Gupta, S., Geva, R., Pusztai, L., Dolled-Filhart, M. P., Emancipator, K., Gonzalez, E. J., et al. (2015) · Cancer Research · doi:10.1158/1538-7445.sabcs14-s1-09 · Cited by 114
Kantekure, K., Yang, Y., Raghunath, P. N., Schaffer, A., Woetmann, A., Zhang, Q., Ødum, N., & Wasik, M. A. (2011) · American Journal of Dermatopathology · doi:10.1097/dad.0b013e31821c35cb · Cited by 112
Advani, R. H., Horning, S. J., Hoppe, R. T., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.2069 · Cited by 112
Richendollar, B. G., Pohlman, B. L., Elson, P. J., & Hsi, E. D. (2011) · Human Pathology · doi:10.1016/j.humpath.2010.08.015 · Cited by 110
Eichenauer, D. A., Plütschow, A., Fuchs, M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.4363 · Cited by 102
Silverberg, M. J., & Abrams, D. I. (2007) · Current Opinion in Oncology · doi:10.1097/cco.0b013e3282c8c90d · Cited by 100
Kearl, T. J., Jing, W., Gershan, J. A., & Johnson, B. D. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202005 · Cited by 99
Tsimberidou, A. M., Braiteh, F., Stewart, D. J., & Kurzrock, R. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.6018 · Cited by 93
Self-citationWeniger, M. A., Gesk, S., Ehrlich, S., Martín-Subero, J. I., Dyer, M. J. S., Siebert, R., Mӧller, P., & Barth, T. F. E. (2007) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20420 · Cited by 92
Deregulated cytokine network and defective Th1 immune response in multiple myeloma
Frassanito, M. A., Cusmai, A., & Dammacco, F. (2001) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.2001.01582.x · Cited by 85
Goodyear, O. C., Piper, K., Khan, N., Starczynski, J., Mahendra, P., Pratt, G., & Moss, P. A. H. (2005) · Blood · doi:10.1182/blood-2005-02-0563 · Cited by 81
Chemnitz, J. M., Eggle, D., Driesen, J., Claßen, S., Riley, J. L., Debey‐Pascher, S., Beyer, M., Popov, A., Zander, T., & Schultze, J. L. (2007) · Blood · doi:10.1182/blood-2006-12-064360 · Cited by 81
Signaling pathway and dysregulation of PD1 and its ligands in lymphoid malignancies
Xia, Y., Medeiros, L. J., & Young, K. H. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.09.002 · Cited by 75
Ji, Y., Wright, G. W., Rosenwald, A., Steidl, C., Gascoyne, R. D., Connors, J. M., Mottok, A., Weisenburger, D. D., Greiner, T. C., Fu, K., et al. (2015) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000473 · Cited by 70
Expression of PD-1 (CD279) and FoxP3 in diffuse large B-cell lymphoma
Ahearne, M. J., Bhuller, K. S., Hew, R., Ibrahim, H., Naresh, K. N., & Wagner, S. D. (2014) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-014-1615-5 · Cited by 70
Chao, C., Page, J. H., Yang, S.-J., Rodríguez, R., Huynh, J., & Chia, V. M. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu203 · Cited by 70
Okiyama, N., & Katz, S. I. (2014) · Journal of Autoimmunity · doi:10.1016/j.jaut.2014.06.005 · Cited by 68
Deng, R., Cassady, K. M., Li, X., Yao, S., Zhang, M., Racine, J. J., Lin, J. J., Chen, L., & Zeng, D. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1402157 · Cited by 67
Olszewski, A. J., Fallah, J., & Castillo, J. J. (2016) · Cancer · doi:10.1002/cncr.30112 · Cited by 58
Chong, L. C., Twa, D. D. W., Mottok, A., Ben‐Neriah, S., Woolcock, B. W., Zhao, Y., Savage, K. J. J., Marra, M. A., Scott, D. W., Gascoyne, R. D., et al. (2016) · Blood · doi:10.1182/blood-2015-11-683003 · Cited by 56
Han, L., Liu, F., Li, R., Li, Z., Chen, X., ZHOU, Z., Zhang, X., Hu, T., Zhang, Y., Young, K. H., et al. (2014) · Oncology Letters · doi:10.3892/ol.2014.2356 · Cited by 53
Update on the treatment of HIV-associated hematologic malignancies
Little, R. F., & Dunleavy, K. M. (2013) · Hematology · doi:10.1182/asheducation-2013.1.382 · Cited by 48
Fenske, T. S., Hamadani, M., Cohen, J. B., Costa, L. J., Kahl, B. S., Evens, A. M., Hamlin, P. A., Lazarus, H. M., Petersdorf, E. W., & Bredeson, C. (2016) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2016.04.019 · Cited by 47
Pingali, S. R., & Champlin, R. E. (2015) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.61 · Cited by 38
Armand, P. A., Shipp, M. A., Ribrag, V., et al. (2015) · Blood · doi:10.1182/blood.v126.23.584.584 · Cited by 36
Chang, X., Zang, X., & Xia, C.-Q. (2015) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.288 · Cited by 29
Structural genomic alterations in primary mediastinal large B-cell lymphoma
Twa, D. D. W., & Steidl, C. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.985673 · Cited by 28
Care, M. A., Westhead, D. R., & Tooze, R. M. (2015) · Genome Medicine · doi:10.1186/s13073-015-0218-3 · Cited by 27
How I treat advanced classical Hodgkin lymphoma
Johnson, P., & McKenzie, H. (2015) · Blood · doi:10.1182/blood-2014-09-551556 · Cited by 26
Effects of indoleamine 2,3-dioxygenase inhibitor in non-Hodgkin lymphoma model mice
Nakamura, N., Hara, T., Shimizu, M., Mabuchi, R., Nagano, J., Ohno, T., Kochi, T., Kubota, M., Shirakami, Y., Goto, N., et al. (2015) · International Journal of Hematology · doi:10.1007/s12185-015-1835-8 · Cited by 23
Younes, A., Santoro, A., Zinzani, P. L., Timmerman, J. M., Ansell, S. M., Armand, P. A., Fanale, M. A., Ratanatharathorn, V., Kuruvilla, J. G., Cohen, J. B., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.7535 · Cited by 15
Identification of T follicular helper (Tfh) cells by flow cytometry
Baumjohann, D., Baumjohann, D., & Ansel, K. M. (2013) · Protocol Exchange · doi:10.1038/protex.2013.060 · Cited by 8
Love the one you're with: the HIV, B cell and TFH cell triangle
Pillai, S. S. (2013) · Nature Medicine · doi:10.1038/nm.3141 · Cited by 5
Cited by
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
Goodman, A. M., Kato, S., Bazhenova, L., Patel, S. P., Frampton, G. M., Miller, V., Stephens, P. J., Daniels, G. A., & Kurzrock, R. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0386 · Cited by 2,264
Self-citationAutophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy
Gao, W., Wang, X., Zhou, Y., Wang, X., & Yu, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01046-3 · Cited by 1,042
(2017) · doi:10.1158/1078-0432.ccr-16-3133 · Cited by 831
Chimeric antigen receptor T-cell therapies for lymphoma
Brudno, J. N., & Kochenderfer, J. N. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.128 · Cited by 516
Crosstalk Between the MSI Status and Tumor Microenvironment in Colorectal Cancer
Lin, A., Zhang, J., & Luo, P. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02039 · Cited by 358
Metadata
- Authors
- Goodman, A., Patel, S. P., & Kurzrock, R.
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2016-11-02
- Volume
- 14
- Issue
- 4
- Pages
- 203-220
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- OpenAlex
- W2546632559
- Cited by
- 461
- References
- 151
- FWCI
- 10.37
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.